We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Designer agent blocks pain in mice without morphine's side effects
News

Designer agent blocks pain in mice without morphine's side effects

Designer agent blocks pain in mice without morphine's side effects
News

Designer agent blocks pain in mice without morphine's side effects

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Designer agent blocks pain in mice without morphine's side effects "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Structure-based molecule selectively targets brain analgesic circuitry -


Scientists have synthesized a molecule with a unique profile of highly specific pain-relieving properties and demonstrated its efficacy in mice. Compared to existing opioid pain relievers, like morphine, the new agent, called PZM21, was not "reinforcing" or prone to triggering potentially lethal respiratory impairment—and was also less constipating. Also unlike existing analgesics, it had little effect on spinal cord reflexive responses, instead targeting the brain-mediated emotional/experiential component of pain. In addition to clinical potential, PZM21 also holds promise as a "tool molecule" for exploring the workings of brain pain systems, say the researchers.


Read Next: Light—not pain-killing drugs—used to activate brain’s opioid receptors


The study represents the combined efforts of National Institutes of Health- (NIH-) funded research teams (US) led by Nobel laureate Brian Kobilka, MD, of Stanford University, Bryan Roth, MD, PhD, of the University of North Carolina, and Brian Shoichet, PhD, of the University of California San Francisco. They report on their findings in the journal Nature.


They achieved PZM21's specificity by applying knowledge of opioid receptor structure to design an agent optimized for just the desired properties. Evidence suggested that the undesirable side effects of morphine-like opiates work on the receptor through a molecular signaling pathway linked to beta-arrestin, while the desired analgesic effects work through a G protein-coupled receptor pathway. The researchers screened and ranked more than 3 million compounds for these properties—evaluating each in about 1.3 million configurations for their ability to tweak the opioid receptor in the desired ways. After exhaustive winnowing, they used the knowledge gained to synthesize the strongest G protein and weakest beta-arrestin activator. PZM21's unprecedented chemical structure then performed just as they had theorized in mouse tests of analgesic and side effect potential.


Learn More: Obesity surgery normalizes brain opioids


"This work demonstrates the power of structure-based design to speed up the development of drugs with optimal signaling and therapeutic properties" explained Laurie Nadler, PhD, chief of the Neuropharmacology Program of the NIH's National Institute of Mental Health, which co-funded the research along with NIH's National Institute of General Medical Sciences and National Institute on Drug Abuse.


Note: Material may have been edited for length and content. For further information, please contact the cited source.


NIH / National Institute of Mental Health   press release


Publication

Manglik A et al. Structure-based discovery of opioid analgesics with reduced side effects.   Nature, Published Online August 17 2016. doi: 10.1038/nature19112


Advertisement